33c share price target by July 2021, page-5

There are many examples of other ASX listed companies whose share price has followed similar crashes only to recover soon after.

The BTX 1503 study results were not clear cut. This was exactly the same for PAR and RAP, where a study produced ambiguous results that did not disprove the science but rather was the result of some external issue. Due to the fact that the core science behind these drugs or products is viable, the share prices recovered and in some cases far surpassed the prices before the release of the results.

In 2017 PAR conducted a Phase 2a allergic rhinitis trial which despite promising results before the phase 2 study failed to meet its endpoints. The issue was not PPS but rather that the drug formulation was at fault, and as a result the treatment was not effective. The share price fell 59% on the news. The company then focused on using PPS for Osteoarthritis and put hay fever on the back burner. Good phase 2 results were achieved in the Osteoarthritis study, and the share price has rallied 1,090% from its lowest point.

RAP is a medical device company that has technology that enables the diagnosis of lung conditions such as bronchitis and pneumonia by coughing into a smartphone running its proprietary software. A study was conducted at the Joondalup Hospital in Perth,which had very strong results. A study was then undertaken in the US which had poor results due to the fact study protocols were not followed. The stock fell 80% but has since recovered by 375% due to the fact the study was repeated in which the correct protocols were followed, and the endpoints were achieved.

I believe BOT is in the same position and with some more data will recover its lost ground.

http://www.botanixpharma.com/wp-content/uploads/14112019-Botanix-Acne-Results-Deep-Dive-002.pdf

T.E.P.